Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis

Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2

(2016) Ulf Schulze-Topphoff et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis

(2016) Rui Li et al.   Frontiers in Immunology

Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS

(2015) Benedetta Parodi et al.   ACTA NEUROPATHOLOGICA

The effect of dimethyl fumarate on gene expression and the level of cytokines related to different T helper cell subsets in peripheral blood mononuclear cells of patients with psoriasis

(2015) Sahar Tahvili et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

DMF, but not other fumarates, inhibits NF-κB activity in vitro in an Nrf2-independent manner

(2015) Geoffrey O. Gillard et al.   JOURNAL OF NEUROIMMUNOLOGY

Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients

(2015) Erin E Longbrake et al.   Multiple Sclerosis Journal

Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy

(2015) Rui Li et al.   Science Translational Medicine

Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients

(2015) Erin E Longbrake et al.   Multiple Sclerosis Journal

IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases

(2014) Ping Shen et al.   NATURE

Oral BG-12 (dimethyl fumarate) for relapsing–remitting multiple sclerosis: a review of DEFINE and CONFIRM

(2013) Eva Havrdova et al.   EXPERT OPINION ON PHARMACOTHERAPY

MHC class II–dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies

(2013) Nicolas Molnarfi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study

(2013) Michael Hutchinson et al.   JOURNAL OF NEUROLOGY

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study

(2013) Amit Bar-Or et al.   JOURNAL OF NEUROLOGY

Dimethyl Fumarate Inhibits Dendritic Cell Maturation via Nuclear Factor κB (NF-κB) and Extracellular Signal-regulated Kinase 1 and 2 (ERK1/2) and Mitogen Stress-activated Kinase 1 (MSK1) Signaling

(2012) Haiyan Peng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells

(2012) Tom A. Barr et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

(2011) Ludwig Kappos et al.   LANCET

CD19+CD24hiCD38hi B Cells Exhibit Regulatory Capacity in Healthy Individuals but Are Functionally Impaired in Systemic Lupus Erythematosus Patients

(2010) Paul A. Blair et al.   IMMUNITY

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

(2009) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

Fumaric Acid and its Esters: An Emerging Treatment for Multiple Sclerosis

(2009) D. Moharregh-Khiabani et al.   Current Neuropharmacology

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

(2008) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) Ludwig Kappos et al.   LANCET

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE